Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Minetta C Liu

Showing results (121-130 of 159) with videos related to

Pageof 16
Sort By:
NPJ Breast Cancer|July 11, 2017
PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)Minetta C Liu, Brandelyn N Pitcher, Elaine R Mardis, et al.
JAMA Oncology|March 9, 2023
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical TrialTufia C Haddad, Vera J Suman, Antonino B D'Assoro, et al.
Journal of Hepatology|November 12, 2024
Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinomaChanghoon Yoo, Hyehyun Jeong, Jae Ho Jeong, et al.
Cell Reports. Medicine|November 7, 2024
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancerMichael J Campbell, Denise M Wolf, Christina Yau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2012
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657Laura J Esserman, Donald A Berry, Angela DeMichele, et al.
JAMA Oncology|July 3, 2026
Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver MetastasesKozo Kataoka, Kazuma Ito, Yoshiaki Nakamura, et al.
The Oncologist|July 18, 2024
Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinomaGregory P Botta, Maen Abdelrahim, Ronald L Drengler, et al.
Nature Communications|April 18, 2023
Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancerJodi M Carter, Saranya Chumsri, Douglas A Hinerfeld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2017
First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast CancerMatthew P Goetz, Vera J Suman, Joel M Reid, et al.
Cancer Immunology Research|December 16, 2021
NKG7 Is a T-cell-Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer ImmunotherapyTi Wen, Whitney Barham, Ying Li, et al.
Pageof 16

Showing results (121-130 of 159) with videos related to

Sort By:
Pageof 16
NPJ Breast Cancer|July 11, 2017
PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)Minetta C Liu, Brandelyn N Pitcher, Elaine R Mardis, et al.
JAMA Oncology|March 9, 2023
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical TrialTufia C Haddad, Vera J Suman, Antonino B D'Assoro, et al.
Journal of Hepatology|November 12, 2024
Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinomaChanghoon Yoo, Hyehyun Jeong, Jae Ho Jeong, et al.
Cell Reports. Medicine|November 7, 2024
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancerMichael J Campbell, Denise M Wolf, Christina Yau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2012
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657Laura J Esserman, Donald A Berry, Angela DeMichele, et al.
JAMA Oncology|July 3, 2026
Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver MetastasesKozo Kataoka, Kazuma Ito, Yoshiaki Nakamura, et al.
The Oncologist|July 18, 2024
Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinomaGregory P Botta, Maen Abdelrahim, Ronald L Drengler, et al.
Nature Communications|April 18, 2023
Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancerJodi M Carter, Saranya Chumsri, Douglas A Hinerfeld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2017
First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast CancerMatthew P Goetz, Vera J Suman, Joel M Reid, et al.
Cancer Immunology Research|December 16, 2021
NKG7 Is a T-cell-Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer ImmunotherapyTi Wen, Whitney Barham, Ying Li, et al.
Pageof 16